Nintedanib for lung scarring from sarcoidosis
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether nintedanib, a drug that slows lung scarring, can help people with sarcoidosis-related lung fibrosis. It is for those who still have breathlessness or cough despite stable treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have sarcoidosis with scarring (fibrosis) on at least 20% of your lung CT scan.
- You have shortness of breath (grade 1 or more) or a cough lasting over 3 months.
- Your lung function is below 80% of normal or your oxygen drops by 4% or more during a 6-minute walk test.
- You have been on a stable dose of steroids or other immune-suppressing drugs for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a steroid medication called compound betamethasone for people with newly diagnosed pulmonary sarcoidosis (stage I or II). It may help reduce inflammation and improve symptoms compared to standard prednisone treatment.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study tests whether adding a cough suppressant called dextromethorphan to the standard IPF medication nintedanib helps improve cough and lung function better than nintedanib alone. It is a 12-week treatment phase with a 1-week follow-up, designed for people with moderate IPF.
This trial tests nintedanib to slow or improve bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a hematopoietic stem cell transplant. You may be considered if your breathing tests and scans show BOS, and if active infections and certain health risks are ruled out.
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
Hear when a new Sarcoidosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.